Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hoyle M"" wg kryterium: Autor


Wyświetlanie 1-11 z 11
Tytuł :
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Autorzy :
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Griffin E; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Lucherini S; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Talens-Bou J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Long L; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Sherriff D; Plymouth Oncology Centre, Plymouth Hospitals NHS Trust, Plymouth, UK.
Napier M; Exeter Oncology Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
Ramage J; Neuroendocrine Tumour Service, King's College Hospital NHS Foundation Trust, London, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2018 Sep; Vol. 22 (49), pp. 1-326.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Everolimus/*therapeutic use
Neuroendocrine Tumors/*drug therapy
Octreotide/*analogs & derivatives
Organometallic Compounds/*therapeutic use
Radioisotopes/*therapeutic use
Sunitinib/*therapeutic use
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/economics ; Antineoplastic Combined Chemotherapy Protocols/economics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cost-Benefit Analysis ; Digestive System Neoplasms/drug therapy ; Digestive System Neoplasms/pathology ; Disease Progression ; Everolimus/adverse effects ; Everolimus/economics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Neoplasm Metastasis ; Neuroendocrine Tumors/pathology ; Octreotide/adverse effects ; Octreotide/economics ; Octreotide/therapeutic use ; Organometallic Compounds/adverse effects ; Organometallic Compounds/economics ; Quality-Adjusted Life Years ; Radioisotopes/adverse effects ; Radioisotopes/economics ; Randomized Controlled Trials as Topic ; Sunitinib/adverse effects ; Sunitinib/economics
Czasopismo naukowe
Tytuł :
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Autorzy :
Dickson R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK. .
Boland A; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Duarte R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Kotas E; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Woolacott N; Centre for Reviews and Dissemination, University of York, York, UK.
Hodgson R; Centre for Reviews and Dissemination, University of York, York, UK.
Riemsma R; Kleijnen Systematic Reviews, York, UK.
Grimm S; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Ramaekers B; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Joore M; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Büyükkaramikli N; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Kaltenthaler E; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Stevenson M; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Pandor A; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Edwards S; BMJ Technology Assessment Group, BMJ, London, UK.
Hoyle M; Peninsula Technology Assessment Group, University of Exeter Medical School, Exeter, UK.
Shepherd J; Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK.
Armoiry X; Warwick Evidence, University of Warwick, Coventry, UK.
Brazzelli M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
Pokaż więcej
Źródło :
Applied health economics and health policy [Appl Health Econ Health Policy] 2018 Aug; Vol. 16 (4), pp. 429-432.
Typ publikacji :
Editorial
MeSH Terms :
Drug Approval*/methods
Drug Approval*/organization & administration
Drug Approval*/statistics & numerical data
Antineoplastic Agents/*therapeutic use
European Union/organization & administration ; Humans ; Uncertainty ; United Kingdom
Opinia redakcyjna
Tytuł :
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Autorzy :
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Briscoe S; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Bond M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Napier M; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2017 Jun; Vol. 21 (38), pp. 1-294.
Typ publikacji :
Journal Article; Review; Systematic Review
MeSH Terms :
Treatment Outcome*
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal/*economics
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*economics
Antineoplastic Agents, Immunological/*administration & dosage
Antineoplastic Agents, Immunological/*economics
Cetuximab/*administration & dosage
Cetuximab/*economics
Colorectal Neoplasms/*drug therapy
Neoplasm Metastasis/*drug therapy
Cost-Benefit Analysis ; Female ; Humans ; Male ; Panitumumab ; Technology Assessment, Biomedical
Czasopismo naukowe
Tytuł :
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Autorzy :
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Crathorne L
Peters J
Jones-Hughes T
Cooper C
Napier M
Tappenden P
Hyde C
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2013 Apr; Vol. 17 (14), pp. 1-237.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents/*therapeutic use
Colorectal Neoplasms/*drug therapy
Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/economics ; Animals ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/economics ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/economics ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/economics ; Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab ; Cetuximab ; Clinical Protocols ; Clinical Trials as Topic ; Colorectal Neoplasms/pathology ; Cost-Benefit Analysis ; Disease-Free Survival ; Humans ; Models, Economic ; Panitumumab ; Quality-Adjusted Life Years ; United Kingdom
Czasopismo naukowe
Tytuł :
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Autorzy :
Hoyle M; PenTAG, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth, UK. martin.hoyle@pms.ac.uk
Crathorne L
Garside R
Hyde C
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2011 May; Vol. 15 Suppl 1, pp. 61-7.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Alemtuzumab ; Antibodies, Monoclonal/economics ; Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/economics ; Clinical Trials as Topic ; Cost-Benefit Analysis ; Disease-Free Survival ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Quality-Adjusted Life Years ; Vidarabine/analogs & derivatives ; Vidarabine/economics ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Autorzy :
Hoyle M; Peninsula Medical School, University of Plymouth, Plymouth, UK. martin.hoyle@pms.ac.uk
Green C
Thompson-Coon J
Liu Z
Welch K
Moxham T
Stein K
Pokaż więcej
Źródło :
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2010 Jan-Feb; Vol. 13 (1), pp. 55-60. Date of Electronic Publication: 2009 Sep 25.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Benzenesulfonates/*economics
Benzenesulfonates/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Pyridines/*economics
Pyridines/*therapeutic use
Carcinoma, Renal Cell/economics ; Chemotherapy, Adjuvant/economics ; Cost-Benefit Analysis ; Decision Support Techniques ; Disease Progression ; Humans ; Kidney Neoplasms/economics ; Markov Chains ; Models, Statistical ; National Health Programs ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Quality-Adjusted Life Years ; Sorafenib ; United Kingdom
Czasopismo naukowe
Tytuł :
Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Autorzy :
Hoyle M; Peninsula Medical School, University of Plymouth, Plymouth, UK. martin.hoyle@pms.ac.uk
Green C
Thompson-Coon J
Liu Z
Welch K
Moxham T
Stein K
Pokaż więcej
Źródło :
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2010 Jan-Feb; Vol. 13 (1), pp. 61-8. Date of Electronic Publication: 2009 Sep 25.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Kidney Neoplasms/*drug therapy
Sirolimus/*analogs & derivatives
Carcinoma, Renal Cell/economics ; Cost-Benefit Analysis ; Decision Support Techniques ; Humans ; Immunologic Factors/economics ; Immunologic Factors/therapeutic use ; Interferon-alpha/economics ; Interferon-alpha/therapeutic use ; Kaplan-Meier Estimate ; Kidney Neoplasms/economics ; National Health Programs ; Quality-Adjusted Life Years ; Sirolimus/economics ; Sirolimus/therapeutic use ; United Kingdom
Czasopismo naukowe
Tytuł :
Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
Autorzy :
Bond M; PenTAG, Peninsula Medical School, Universities of Exeter and Plymouth, Exeter, UK. />Hoyle M
Moxham T
Napier M
Anderson R
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2009 Sep; Vol. 13 Suppl 2, pp. 69-74.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Gastrointestinal Stromal Tumors/*drug therapy
Indoles/*economics
Indoles/*therapeutic use
Pyrroles/*economics
Pyrroles/*therapeutic use
Cost-Benefit Analysis ; Drug Industry ; Humans ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Sunitinib
Czasopismo naukowe
Tytuł :
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Autorzy :
Thompson Coon, J. S.
Liu, Z.
Hoyle, M.
Rogers, G.
Green, C.
Moxham, T.
Welch, K.
Stein, K.
Pokaż więcej
Temat :
BEVACIZUMAB
ANTINEOPLASTIC agents
RENAL cell carcinoma
CANCER treatment
MEDICAL research
METASTASIS
RENAL cancer
CANCER patients
Źródło :
British Journal of Cancer; 7/21/2009, Vol. 101 Issue 2, p238-243, 6p, 1 Diagram, 4 Charts
Czasopismo naukowe
    Wyświetlanie 1-11 z 11

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies